CompletedInterventionalPhase 3Updated Aug 21, 2019
Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity | NCT00651729 | Trialant
CompletedInterventionalPhase 2Updated May 28, 2008
Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity
ClinicalTrials.gov ID
NCT00651729
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Enrollment
279Actual
Last Update Posted
May 28, 2008Estimated
Start Date
Apr 2003
Primary Completion Date
Dec 2004Actual
Completion Date
Dec 2004Actual
Brief Summary
The purpose of this study is to evaluate the safety of repeated doses of Botulinum Toxin Type A for the treatment of focal upper limb poststroke spasticity
Stroke
Muscle Spasticity
Botulinum Toxin Type A
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Medically stable poststroke patients with spastic muscles in the upper limb
Exclusion Criteria:
Stroke within 6 months of study enrollment
Previous therapy with Botulinum Toxin Type A for treatment of any condition prior to 4 months of enrollment, for treatment of any condition prior to 01 January 1998